
    
      Participants will be screened prior to the start of the study drug for eligibility.

      Eligible participants will take CFI-400945 by mouth, once a day, every day of each 28 day
      cycle. Participants will be asked to keep a study drug diary.

      While receiving the study drug, participants will have standard tests and procedures done for
      safety purposes.

      Procedures for research purposes include bone marrow aspirate and additional blood collection
      for biomarker research, and additional blood samples for pharmacokinetic research.

      When participants stop the study drug permanently for any reason, they will be asked to have
      an End of Treatment Visit and be followed for safety purposes.
    
  